Видео ютуба по тегу Biocon Growth Potential

Biocon Equity Raise, Anand Rathi AUM Growth, HDFC Bank Valuations & Top Sector Picks | Business News
Biocon Equity Raise, Anand Rathi AUM Growth, HDFC Bank Valuations & Top Sector Picks | Business News
Debut Diaries
Debut Diaries
Biocon Biologics Around the World
Biocon Biologics Around the World
Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space
Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space
Узнайте о глобальной возможности привлечения 7 миллиардов долларов для двух биоаналогов деносумаб...
Узнайте о глобальной возможности привлечения 7 миллиардов долларов для двух биоаналогов деносумаб...
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Biocon Gets US FDA Approval for Everolimus Tablets: Key Growth Trigger Explained
Biocon Gets US FDA Approval for Everolimus Tablets: Key Growth Trigger Explained
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
How Biocon Is Driving Market Expansion
How Biocon Is Driving Market Expansion
"Biocon Stock: What Investors Need to Know in 2024"
Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO
Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO
Biocon Initiates Talks for Potential Stake Sale in Biosimilar Arm & Syngene | ET Now Exclusive
Biocon Initiates Talks for Potential Stake Sale in Biosimilar Arm & Syngene | ET Now Exclusive
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Biocon's Big Move: Japanese Drug Approval and the Future of Biosimilars
Biocon's Big Move: Japanese Drug Approval and the Future of Biosimilars
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Investec Initiates 'Buy' On Biocon; What Key Growth Drivers For The Company? | NDTV Profit
Investec Initiates 'Buy' On Biocon; What Key Growth Drivers For The Company? | NDTV Profit
BIOCON-CO2 webinar series, episode 1: BIO-CCU potentials and opportunities
BIOCON-CO2 webinar series, episode 1: BIO-CCU potentials and opportunities
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
R&D spending: Our pipeline is our 'lifeline,' says Indian biotech firm
R&D spending: Our pipeline is our 'lifeline,' says Indian biotech firm
Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership
Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership